Sunday Edition: An Underdog Penny Stock with Big Possibilities in the Fight Against Cancer— Pela (ONCY)

 

An Underdog Penny Stock with Big Possibilities in the Fight Against Cancer — Pela (ONCY)

Earlier Jones Reports have explored some intriguing "what if" possibilities surrounding Oncolytics Biotech (ONCY) and its experimental cancer treatment, Pelareorep — or Pela.

Before going any further into the "what ifs," let's remind ourselves that this is speculation, based on "some" encouraging scientific evidence from relatively small clinical trials. But let's also remember that many of these trials have involved patients with advanced cancers, often with few treatment options remaining.  Perhaps an urgent unmet need to help courageous cancer fighters is one reason the FDA seems to be engaging more closely with Oncolytics lately. At the same time, let's not forget that putting real money into even "some" shares of an underdog penny stock carries risk. So let's keep our expectations humble.

Pela is a naturally occurring reovirus, first studied during the polio research era of the 1950s, including work by famed polio vaccine pioneer Dr. Albert Sabin. Today, that virus is cultivated and amplified into an experimental IV treatment designed to stimulate the body's immune response against cancer.

Now, with initial results from the REO-033 colorectal cancer trial anticipated around year's end, another important "what if" is approaching.

Recall that the earlier, small REO-022 trial produced an impressive 33% objective response rate (ORR) compared with historical standard-of-care benchmarks of approximately 6–11%. The trial also reported encouraging evidence of longer survival.

REO-033 is designed to determine whether those results can be reproduced in a randomized clinical trial.

Importantly, Pela has already received FDA Fast Track designation, and Oncolytics and the FDA have made significant progress toward establishing a potential pivotal expansion of REO-033, with ORR serving as a possible basis for accelerated approval.

Consider the possibilities.

What if the initial REO-033 results begin to confirm the earlier findings? Or better yet, what if they exceed them substantially?

Could such results prompt the FDA to consider an extraordinary acceleration of Pela's development and potential approval?

And here is another intriguing possibility.

Could Pela become a candidate for FDA Breakthrough Therapy designation?

There is an interesting historical precedent.

Merck's blockbuster cancer immunotherapy Keytruda received Breakthrough Therapy designation in January 2013, followed by its initial FDA approval in September 2014.

But consider something else about Keytruda.

Despite its remarkable success in treating several cancers, evidence has demonstrated that Keytruda alone is often ineffective against immunologically "cold" tumors, particularly microsatellite-stable colorectal cancers.

In fact, one early clinical study reported no objective responses among 18 patients with mismatch-repair-proficient colorectal cancer treated with Keytruda.

And that brings us back to Pela...

Earlier clinical studies have demonstrated Pela's ability to stimulate immune activity within tumors, potentially providing the very immune activation that treatments such as Keytruda need to become more effective against otherwise resistant cancers.

Pancreatic cancer tumor biopsy — immune-cell activity

Figure 8 : Distinct Distribution of Tumor Infiltrating Leukocyte (TIL) populations and Metabolic Alteration

study: https://oncolyticsbiotech.com/wp-content/uploads/2022/12/ASCO-2021_final.pdf

These studies have also demonstrated a generally favorable safety profile, with encouraging evidence of longer survival in certain cancer treatment combinations.

Although REO-033 is not testing Pela with Keytruda, compelling results could strengthen interest in Pela's broader potential as an adjunct to existing cancer treatments.

And what about Big Pharma?

Could extraordinary REO-033 results, potentially followed by Breakthrough Therapy designation, suddenly change the level of interest among major pharmaceutical companies?

Might licensing agreements, development partnerships, or even acquisition possibilities begin taking on an entirely different dimension?

After all, Pela's potential application across multiple cancer types could represent a much larger opportunity than colorectal cancer alone.

And consider another possibility.

Because Pela is administered separately from existing cancer treatments, one can envision a future where patients might visit convenient outpatient infusion clinics to receive Pela as an adjunct therapy, under the direction of their oncologists.

Such a development could open an entirely new dimension in the delivery of cancer treatment.

Now, consider the bigger picture.

For years, the vision has been that a naturally occurring virus could become the missing piece that helps existing cancer treatments save more lives.

Earlier Jones Reports coined the term "The Trinity Approach" — envisioning the potential combination of Pela with checkpoint inhibitors and antibody-drug conjugates.

But perhaps there's another intriguing dimension to that name.

Consider a virus provided by nature, studied decades ago by Dr. Sabin, and now cultivated and amplified by Oncolytics into a potential weapon against cancer.

Could there even be a touch of divine Providence in this long journey? Who knows?

Again, let's stay humble in our expectations and keep it to the science.  After all, ONCY trades well under a buck, and its following seems largely confined to a group of us retail scientists, believers, and hopefuls.

And as earlier Jones Reports have suggested, I now proclaim that a wake-up call may be coming for institutional money managers. If the initial REO-033 ORR readout points convincingly upward, perhaps Wall Street will finally begin taking a closer look at this underdog penny stock.

What might that mean for Oncolytics itself?

Could today's underdog penny stock eventually emerge as a key player in the fight against cancer?

Perhaps the approaching REO-033 results will begin to tell us whether some of these extraordinary possibilities could become reality.

For a little penny stock with such enormous potential, that would be quite a story.

This report has presented some intriguing "what if" scenarios.

For those of us willing to take a chance on something with the potential to make a real difference, perhaps owning just "some" shares is a way to be part of it.

But perhaps - not too many to limit the risk.

Let it be known that I still personally hold 1000 ONCY retail shares, now under a buck.  Although they are seemingly embattled shares during the wait for the initial readout - I want to see what is actually about to develop with Pela advancement.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations. 

Sunday Edition — Penny Stock ONCY: How “THINGS” Can Yet Get VERY Interesting — More “Dot Talk”

 

Stock Talk

Oncolytics Biotech (ONCY) is sitting under $1 and remains an underdog speculative biotech stock.  Folks, before delving further here, let's be honest. With penny stocks, each has its reason for being there.

This report looks at both the bear and the bull of the matter. Yet within that uncertainty may hold opportunity.  To address risk, we often use the words:

Maybe some — not too much.

There is also Nasdaq listing risk if ONCY remains below the $1 minimum bid requirement long enough to fall out of compliance.

But something IS different this time.

With biotech trials, things typically take years to know the outcomes — positive or negative.

With ONCY, that tired script may be changing. Early Objective Response Rate (ORR) results from the new REO-033 colorectal cancer trial are expected in just months, NOT years.

That makes the early ORR readout very important. It could provide the first indication of whether Pelareorep (Pela) is working and help determine whether ONCY moves toward the larger pivotal Part B.

So, let's talk “What IF?” for a moment.

What IF early treatment in the Pela REO-033 arm shows obvious and outstanding results in tumor reductions?

What could that set in motion?

And why could the results of a small earlier trial called REO-022 suddenly become very important?

Perhaps earlier Pela results helped get the FDA's attention.

Remember, this follows the historical results of the small REO-022 trial — and other small Pela trials in which significant responses have been reported. In advanced anal cancer, for example, two Complete Responses (CRs) were reported among 14 evaluable third-line patients receiving Pela plus atezolizumab.

Many skeptics will point to a long road of small trials and the failure, so far, to advance Pela successfully through larger trial settings.

The word “history” is frequently used by disgruntled shareholders, shorts and naysayers when discussing ONCY.

But new management has taken steps forward and reached important regulatory milestones, including alignment with the FDA on trial planning that could potentially streamline the path toward approval.

Meanwhile, ONCY continues to generate spirited discussion among retail investors on various stock forums.

From Jones' view, that “buzz” seems to be growing lately.

Something has changed. So let's examine the dots — and where they may even lead.

Dot Talk

This report is specific to speculation on things that “could” happen “if” the results of an earlier cancer trial called REO-022 repeat in the larger colorectal cancer trial now underway.

First, an important caveat. REO-022 was a small study. The colorectal cancer group discussed here consisted of 15 patients, and comparisons with standard-of-care results are historical rather than from a control group in the same trial.

Still, the numbers got attention.

The REO-022 results, as reported by ONCY, were:

ORR (Objective Response Rate): 33% (vs. approximately 6–11% historical)

Median PFS (Progression-Free Survival): 16.6 months (vs. 5.7 months historical)

Median OS (Overall Survival): 27.0 months (vs. 11.2 months historical)

Reference: Oncolytics Biotech, February 4, 2026 — “Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer.”

Now Comes REO-033

REO-033 is designed to put those earlier results to a much tougher test. Part A will enroll approximately 60 patients, divided into two groups of about 30 patients each.

One group receives the standard treatment of FOLFIRI (chemotherapy) plus bevacizumab (generic Avastin by Roche/Genentech).

The other receives the same treatment plus Pela.

This time, Pela will not be compared only with historical results. The trial will directly compare patients receiving Pela with patients in the same trial receiving the same treatment without Pela.

And one of the first things to watch will be ORR — Objective Response Rate.

Early ORR could be THE first major indication of whether REO-033 is succeeding — or running into trouble.

And that brings us to the “IFs.”

IF #1 — Does REO-022 Repeat?

IF the Pela group begins showing an ORR anywhere near the 33% reported in REO-022 — while the group without Pela remains substantially lower — “things” could start getting interesting very quickly.

That would provide something REO-022 could not: a direct comparison between patients receiving Pela and patients in the same trial receiving the same treatment without Pela.

IF #2 — What Could Early ORR Set in Motion?

ONCY does not necessarily have to wait years for mature PFS and OS results before “things” start happening.

IF early Part A ORR results are strong enough, they could help support ONCY's decision to move into the larger pivotal Part B and provide the basis for further discussions with the FDA.

So IF early ORR is strong, the direction of the Pela program could become much clearer long before the final survival numbers are known.

IF #3 — Could This Lead Toward Accelerated Approval?

This is where the FDA pathway becomes important.

The FDA has provided written feedback on a proposed pivotal Part B in which ORR and duration of response could potentially support accelerated approval, while PFS could support full approval.

Final agreement on key elements of the registration program would still require further FDA discussions.

So, the potential path is:

Strong Part A results → further FDA discussions → pivotal Part B → potential accelerated approval based on ORR and duration of response.

That's a significant “IF” — but it is now a regulatory path that ONCY and the FDA have actually discussed.

IF #4 — What About More Patients?

There is another important difference between REO-022 and REO-033.

REO-022 produced its reported results in patients with KRAS-mutant cancer.

REO-033 has broadened the study to patients with RAS-mutant cancer, which includes KRAS as well as other RAS mutations.

That creates both risk and opportunity.

IF Pela does not work as well across this broader group, it could weaken the overall results.

But IF Pela works well across the broader RAS population, many more cancer patients could potentially become eligible for treatment.

And that could mean addressing a larger unmet need.

IF #5 — What IF One Group Responds and Another Doesn't?

REO-033 knows the mutation characteristics of the patients entering the study.

So, what IF the KRAS patients respond strongly to Pela but another RAS subgroup doesn't?

That could help identify which cancer patients benefit most from Pela and potentially influence how ONCY designs or focuses Part B.

Now flip that “IF.”

What IF strong responses show up across the broader RAS population?

Then Pela may not only be repeating the REO-022 story.

It could be expanding it.

There are a lot of “IFs” here.

Some could turn out positive. Some could turn out negative.

But unlike many biotech stories, investors may not have to wait years before the first important answers begin arriving.

Early ORR should begin telling the story.

IF it disappoints, that will tell us something.

But IF REO-033 begins showing the kind of response seen in REO-022, then some of these “IFs” could start becoming reality.

And that's when...

“Things” could get VERY interesting.

Enough “IFs!”

Show me the damn ORR — and let's see.

Coming soon enough, it seems.

The Jones Take

In my last post, I wrote about finding opportunity in uncertainty.

Readers should also know that I previously wrote about The Trinity Approach. That represents my personal conviction that there may be something special about Pelareorep as a missing immune activator that current cancer treatments need to become more effective.

That said, I will not suggest anybody buy hordes of ONCY stock — or even buy any.

But for me, I can say this:

I personally intend to maintain a position of 1,000 ONCY shares while further CRC data is reported on the ORR.  And if “things” work out, I may own more.

That's my speculation. That's my retail risk.

And in closing, I have absolutely ZERO affiliation with ONCY or any outlet. I'm just another hopeful watcher who believes there may be something to this Pela — adapted from nature to help the fighters fight.

Some — not too much.

And stay watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations. 

Trying to Find “Some” Opportunity — When the Fed Raises Rates and Risk

 

Stock Talk

Oncolytics Biotech (ONCY) is sitting under $1 and remains an underdog speculative biotech stock.  Folks, before delving further here, let's be honest. With penny stocks, each has its reason for being there.

This report looks at both the bear and the bull of the matter. Yet within that uncertainty may hold opportunity.  To address risk, we often use the words:

Maybe some — not too much.

There is also Nasdaq listing risk if ONCY remains below the $1 minimum bid requirement long enough to fall out of compliance.

But something IS different this time.

With biotech trials, things typically take years to know the outcomes — positive or negative.

With ONCY, that tired script may be changing. Early Objective Response Rate (ORR) results from the new REO-033 colorectal cancer trial are expected in just months, NOT years.

That makes the early ORR readout very important. It could provide the first indication of whether Pelareorep (Pela) is working and help determine whether ONCY moves toward the larger pivotal Part B.

So, let's talk “What IF?” for a moment.

What IF early treatment in the Pela REO-033 arm shows obvious and outstanding results in tumor reductions?

What could that set in motion?

And why could the results of a small earlier trial called REO-022 suddenly become very important?

Perhaps earlier Pela results helped get the FDA's attention.

Remember, this follows the historical results of the small REO-022 trial — and other small Pela trials in which significant responses have been reported. In advanced anal cancer, for example, two Complete Responses (CRs) were reported among 14 evaluable third-line patients receiving Pela plus atezolizumab.

Many skeptics will point to a long road of small trials and the failure, so far, to advance Pela successfully through larger trial settings.

The word “history” is frequently used by disgruntled shareholders, shorts and naysayers when discussing ONCY.

But new management has taken steps forward and reached important regulatory milestones, including alignment with the FDA on trial planning that could potentially streamline the path toward approval.

Meanwhile, ONCY continues to generate spirited discussion among retail investors on various stock forums.

From Jones' view, that “buzz” seems to be growing lately.

Something has changed. So let's examine the dots — and where they may even lead.

Dot Talk

This report is specific to speculation on things that “could” happen “if” the results of an earlier cancer trial called REO-022 repeat in the larger colorectal cancer trial now underway.

First, an important caveat. REO-022 was a small study. The colorectal cancer group discussed here consisted of 15 patients, and comparisons with standard-of-care results are historical rather than from a control group in the same trial.

Still, the numbers got attention.

The REO-022 results, as reported by ONCY, were:

ORR (Objective Response Rate): 33% (vs. approximately 6–11% historical)

Median PFS (Progression-Free Survival): 16.6 months (vs. 5.7 months historical)

Median OS (Overall Survival): 27.0 months (vs. 11.2 months historical)

Reference: Oncolytics Biotech, February 4, 2026 — “Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer.”

Now Comes REO-033

REO-033 is designed to put those earlier results to a much tougher test. Part A will enroll approximately 60 patients, divided into two groups of about 30 patients each.

One group receives the standard treatment of FOLFIRI (chemotherapy) plus bevacizumab (generic Avastin by Roche/Genentech).

The other receives the same treatment plus Pela.

This time, Pela will not be compared only with historical results. The trial will directly compare patients receiving Pela with patients in the same trial receiving the same treatment without Pela.

And one of the first things to watch will be ORR — Objective Response Rate.

Early ORR could be THE first major indication of whether REO-033 is succeeding — or running into trouble.

And that brings us to the “IFs.”

IF #1 — Does REO-022 Repeat?

IF the Pela group begins showing an ORR anywhere near the 33% reported in REO-022 — while the group without Pela remains substantially lower — “things” could start getting interesting very quickly.

That would provide something REO-022 could not: a direct comparison between patients receiving Pela and patients in the same trial receiving the same treatment without Pela.

IF #2 — What Could Early ORR Set in Motion?

ONCY does not necessarily have to wait years for mature PFS and OS results before “things” start happening.

IF early Part A ORR results are strong enough, they could help support ONCY's decision to move into the larger pivotal Part B and provide the basis for further discussions with the FDA.

So IF early ORR is strong, the direction of the Pela program could become much clearer long before the final survival numbers are known.

IF #3 — Could This Lead Toward Accelerated Approval?

This is where the FDA pathway becomes important.

The FDA has provided written feedback on a proposed pivotal Part B in which ORR and duration of response could potentially support accelerated approval, while PFS could support full approval.

Final agreement on key elements of the registration program would still require further FDA discussions.

So, the potential path is:

Strong Part A results → further FDA discussions → pivotal Part B → potential accelerated approval based on ORR and duration of response.

That's a significant “IF” — but it is now a regulatory path that ONCY and the FDA have actually discussed.

IF #4 — What About More Patients?

There is another important difference between REO-022 and REO-033.

REO-022 produced its reported results in patients with KRAS-mutant cancer.

REO-033 has broadened the study to patients with RAS-mutant cancer, which includes KRAS as well as other RAS mutations.

That creates both risk and opportunity.

IF Pela does not work as well across this broader group, it could weaken the overall results.

But IF Pela works well across the broader RAS population, many more cancer patients could potentially become eligible for treatment.

And that could mean addressing a larger unmet need.

IF #5 — What IF One Group Responds and Another Doesn't?

REO-033 knows the mutation characteristics of the patients entering the study.

So, what IF the KRAS patients respond strongly to Pela but another RAS subgroup doesn't?

That could help identify which cancer patients benefit most from Pela and potentially influence how ONCY designs or focuses Part B.

Now flip that “IF.”

What IF strong responses show up across the broader RAS population?

Then Pela may not only be repeating the REO-022 story.

It could be expanding it.

There are a lot of “IFs” here.

Some could turn out positive. Some could turn out negative.

But unlike many biotech stories, investors may not have to wait years before the first important answers begin arriving.

Early ORR should begin telling the story.

IF it disappoints, that will tell us something.

But IF REO-033 begins showing the kind of response seen in REO-022, then some of these “IFs” could start becoming reality.

And that's when...

“Things” could get VERY interesting.

Enough “IFs!”

Show me the damn ORR — and let's see.

Coming soon enough, it seems.

The Jones Take

In my last post, I wrote about finding opportunity in uncertainty.

Readers should also know that I previously wrote about The Trinity Approach. That represents my personal conviction that there may be something special about Pelareorep as a missing immune activator that current cancer treatments need to become more effective.

That said, I will not suggest anybody buy hoards of ONCY stock — or even buy any.

But for me, I can say this:

I personally intend to maintain a position of 1,000 ONCY shares while further CRC data is reported on the ORR.  And if “things” work out, I may own more.

That's my speculation. That's my risk.

And in closing, I have absolutely ZERO affiliation with ONCY or any outlet. I'm just another hopeful watcher who believes there may be something to this Pela — adapted from nature to help the fighters fight.

Some — not too much.

And stay watchful.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations. 

Special September 11 Jones Report With Market and Stock Talk

 

Special September 11 Jones Report

Today, September 11, 2026, marks 25 years since the attacks on the Twin Towers of the World Trade Center and the Pentagon, and since the passengers and crew of United Flight 93 lost their lives near Shanksville, Pennsylvania.

There is another number worth recognizing. This year also marks the 250th anniversary of America.

Twenty-five years since 9/11. Two hundred and fifty years of America.

There is powerful symbolism in those numbers — and a troubling contrast.

On September 11, 2001, America's enemies attacked this country from the outside. Today, while external threats remain, America must also recognize growing threats from within.

One such threat is radical jihadist ideology. Its adherents can exploit the very constitutional rights and liberties that distinguish America in order to spread a radical interpretation of Islamic doctrine, with the ultimate objective of replacing our system of government and law with their version of Sharia law.

That presents America with a difficult but essential challenge: defending the constitutional freedoms that define this country while remaining vigilant against those who would use those same freedoms in an effort to undermine it.

As America approaches the midterm elections this November, too many have forgotten or seem unaware of the external and growing internal threats facing this great country.

I urge readers to consider voting for those who recognize these threats and understand the words of Benjamin Franklin.

As Benjamin was leaving the Constitutional Convention in 1787, he was asked what form of government the delegates had created.

His famous reply:

“A Republic, if you can keep it.”

And with that said, let's move to the markets and stocks.

Market Talk

There is plenty to talk about. But the Jones Report prefers to keep things brief.

First, many pundits are already speculating on just how the midterm election cycle may affect the markets. Just as important to market watchers are the conclusions being drawn from predictions that the past will repeat itself.

It has been pointed out that in prior midterm years, the lead-up to the elections has often not been favorable to the markets, with corrections often followed by a resurgence in stock values.

When it comes to the exact future “this time” — nobody knows!

There are things happening, though, that at best “seem to” point to some areas to watch for possible positive returns through the trouble.

Before venturing further into such notions, the volatility of the first half of this year, along with the channel churning and sector rotations, is a reminder to some of us — keep a good share of the powder DRY.

Stock Talk

It is now six months into the Iran conflict. Without rehashing the back-and-forth drama of war and peace negotiations, a hard look at where we are today may be useful.

With much of Iran's conventional military capability diminished, the U.S. and its allies appear to have the upper hand.

However, Iran — more specifically, the IRGC — still has the capability to create considerable regional turmoil around the Strait of Hormuz.

While oil flows through the Strait have modestly recovered, the conflict and attacks on ships continue.

Meanwhile, oil prices have pushed above $100 per barrel, with gasoline prices rising sharply and the effects being felt around the world.

Two companies highlighted here that produce oil and gas in the basins of the USA are Devon Energy (DVN) and Permian Resources (PR).

These two remain watch stocks, with possible further upside yet to come as global oil supplies remain strained and America's strategic reserves sit at historically low levels.

Moving on to metals, specifically gold and silver — and yet again to two miners watched here.

Perhaps it should be noted that recently we saw the miners correct even though their earnings were quite good. It seemed that the stock handlers simply did not want to give the miners the respect they were earning. One excuse was that higher energy costs can affect All-In Sustaining Costs (AISC) of production.

While true, the smart guys seemed to forget something: gold and silver prices have more than doubled from the not-too-distant past.  One thing that makes me cautious is that old habits die hard with money managers until they are taught a new lesson. It remains to be seen on the miners, but gingerly placed positions may pay off over time.

In a world where countries around the globe, including our own, continue to increase national debt, those miners producing gold and silver appear to offer more value than many stocks whose earnings seem nowhere near enough to justify some lofty stock prices.  At some point as earnings show sustained high levels, the market may begin giving these miners more of the respect their earnings deserve.  Kinross Gold (KGC) and leading U.S. silver producer Hecla Mining (HL) remain two stock picks to watch.  However, if oil exceeds $100 much longer, be aware of "old habits" of money managers.

These are a few thoughts on oil and gold sectors.  Future reports will opine on many market forces and stocks to come.

- Jones Report

This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?

________

If interested - scroll back and view notes on other stocks, we watch here at the Jones report.  Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions.  Finally - maintain some dry powder and trade or invest according to your own due diligence.

______________

More later so ....Stay tuned, if you dare!

For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality.  Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor. 

All in all - we use the word maybe "some", not "too much" and play it accordingly.  Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.

With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.

___________

ALL in my humble opinion, scroll down and read more.  This site does NOT make Buy / Sell recommendations.